Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial

BACKGROUND: Acute respiratory distress syndrome (ARDS) is the devastating complication of the new COVID-19 pandemic, directly correlated with releasing large amounts of inflammatory cytokines. Due to their immunoregulatory features, mesenchymal stromal cells (MSCs) provide a promising approach again...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaffash Farkhad, Najmeh, Sedaghat, Alireza, Reihani, Hamidreza, Adhami Moghadam, Amir, Bagheri Moghadam, Ahmad, Khadem Ghaebi, Nayereh, Khodadoust, Mohammad Ali, Ganjali, Rashin, Tafreshian, Amir Reza, Tavakol-Afshari, Jalil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241239/
https://www.ncbi.nlm.nih.gov/pubmed/35765103
http://dx.doi.org/10.1186/s13287-022-02920-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241239/
https://www.ncbi.nlm.nih.gov/pubmed/35765103
http://dx.doi.org/10.1186/s13287-022-02920-1

Ejemplares similares